Combination of immunotherapies with activators of Tie-2
AssigneeAerpio Therapeutics Inc.
InventorKevin Peters
Life of this patent
Estimating the term…
Abstract
The present invention relates to combination therapies comprising at least one activator of Tie-2 and immunotherapies that target immune checkpoints. Combination therapies of the disclosure can provide therapeutic effects not obtained with singly-administered immunotherapies. Combination therapies can be used to increase the therapeutic efficacy of an immunotherapy, to provide lower dosages of an immunotherapy being administered, to lower a toxicity of an immunotherapy, or to manage a side effect of an immunotherapy.
Claims40
A method of treating cancer, the method comprising administering to a subject in need thereof:
- a) a therapeutically-effective amount of a Tie-2 activator;
- and
- b) a therapeutically-effective amount of a modulator of an immune checkpoint molecule.
A pharmaceutical composition comprising:
- a) a Tie-2 activator;
- and
- b) a modulator of an immune checkpoint molecule, wherein the Tie-2 activator and the modulator of the immune checkpoint molecule are in the same unit dosage form.
Dependencies are inferred from the claim text.